Boston-based a2z Radiology AI has received FDA clearance for its CT triage system that flags seven urgent findings on abdomen-pelvis scans in a single pass.
The system identifies and prioritises small bowel obstruction, acute cholecystitis (gallbladder inflammation), acute pancreatitis (pancreas inflammation), acute diverticulitis (colon inflammation), hydronephrosis (kidney swelling), free air (air outside organs) and unruptured abdominal aortic aneurysm (bulging artery).
The technology processes scans in minutes, moving suspected emergencies to the top of radiologists’ worklists for faster care. In clinical practice, triage means sorting cases by urgency so the sickest patients are seen first.
Abdomen-pelvis CT is the highest-volume CT category in the US, with over 20 million examinations annually. The company says this is the first US system to triage seven urgent conditions in one pass.
“We set out to build a generalist system that could scale across conditions,” said Pranav Rajpurkar, co-founder of a2z Radiology AI and associate professor at Harvard Medical School. We are starting with high-consequence acute conditions, cases where rapid triage can have the greatest immediate impact on patient care.”
“For five of these seven conditions, we’re bringing AI triage to the US market for the first time. And we’re not stopping at seven. There’s still a lot of scaling ahead,” said Samir Rajpurkar, co-founder and chief executive officer.
The announcement comes days before RSNA 2025, radiology’s largest annual conference, where the company will position itself in the abdomen-pelvis AI market.
a2z Radiology AI was co-founded by Pranav Rajpurkar, a Harvard professor specialising in generalist medical AI, and Samir Rajpurkar, a technology industry veteran. The team combines AI research with clinical expertise from practising radiologists.
